Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PDXK | O00764 | 1/20 | 0.38 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.37 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.37 |
| ▸ | VRK1 | Q99986 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31184201 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1HPGDHSD17B10CCR1 | |
| SCHEMBL9656230 | 0.81 | KDM4E (0.45) | KDM4EALDH1A1HPGDHSD17B10CCR1 | |
| SCHEMBL9332858 | 0.79 | ALDH1A1 (0.39) | KDM4EALDH1A1HPGDHSD17B10CCR1 | |
| SCHEMBL2260982 | 0.79 | KDM4E (0.43) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Methane SCHEMBL6846367 | 0.77 | KDM4E (0.42) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL25035025 | 0.75 | VRK1 (0.41) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL11707220 | 0.75 | NOS3 (0.43) | KDM4EALDH1A1CCR1CCR5CCR8 | |
| SCHEMBL9164063 | 0.75 | CCR1 (0.38) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL874915 | 0.75 | CCR1 (0.46) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL4321859 | 0.73 | KDM4E (0.39) | KDM4EALDH1A1HPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552790-B2 | Positive modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260035366-A1 | POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNIV VANDERBILT (US) | 2026-02-05 | — | — | US | disclosed |
| US-12448380-B2 | Positive modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2025-10-21 | — | — | US | disclosed |
| US-12398117-B2 | Heteroarylamidopyridinol derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of autoimmune disease | INNOVO THERAPEUTICS INC. (KR) | 2025-08-26 | — | — | US | disclosed |
| US-20250228811-A1 | Triester Compounds And Methods Of Use Thereof | LIFEMINE THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-12344608-B2 | Positive modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2025137071-A2 | TRIESTER COMPOUNDS AND METHODS OF USE THEREOF | LIFEMINE THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250136600-A1 | POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2025-05-01 | — | — | US | disclosed |
| US-20250122199-A1 | POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2025-04-17 | — | — | US | disclosed |
| US-20250122200-A1 | POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2025-04-17 | — | — | US | disclosed |
| WO-2014171801-A1 | AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE COMPONENT | 영남대학교 산학협력단 (KR) | 2014-10-23 | — | — | WO | disclosed |
| WO-2014086704-A1 | SUBSTITUTED ISOXAZOLE AMIDE COMPOUNDS AS INHIBITORS OF STEAROYL-COA DESATURASE 1 (SCD1) | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| WO-2013095060-A1 | 6-AMINOPYRIDINE-3-OL DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENTS FOR PREVENTING OR TREATING DISEASES CAUSED BY ANGIOGENESIS | 영남대학교 산학협력단 (KR) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013095060-A1 | 6-AMINOPYRIDINE-3-OL DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENTS FOR PREVENTING OR TREATING DISEASES CAUSED BY ANGIOGENESIS | 영남대학교 산학협력단 (KR) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013019874-A9 | VITAMIN B6 DERIVATIVES OF NUCLEOTIDES, ACYCLONUCLEOTIDES AND ACYCLONUCLEOSIDE PHOSPHONATES | MBC PHARMA, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013019874-A1 | VITAMIN B6 DERIVATIVES OF NUCLEOTIDES, ACYCLONUCLEOTIDES AND ACYCLONUCLEOSIDE PHOSPHONATES | MBC PHARMA, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| EP-2231604-A1 | PREPARATIONS CONTAINING PYRIDOXINE AND ALPHA-HYDROXYISOCAPROIC ACID (HICA) | Northern Innovations and Formulations Corp. (CA) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009073943-A1 | PREPARATIONS CONTAINING PYRIDOXINE AND ALPHA-HYDROXYISOCAPROIC ACID (HICA) | IOVATE T. & P. INC. (CA) | 2009-06-18 | — | — | WO | disclosed |
| US-20090156647-A1 | Method for maintaining physiological pH levels during intensive physical exercise | IOVATE T. & P. INC. (CA) | 2009-06-18 | — | — | US | disclosed |
| US-20090156648-A1 | Preparations containing pyridoxine and alpha-hydroxyisocaproic acid (HICA) | IOVATE T. & P. INC. (CA) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122200-A1 | POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM1, CHRM3 | KDM4E 753/4885ALDH1A1 2993/4885HPGD 1730/4885 |
| US-12552790-B2 | Positive modulators of the muscarinic acetylcholine receptor M4 | CHRM4, CHRM1, CHRM5 | KDM4E 437/4885ALDH1A1 2392/4885HPGD 3652/4885 |
| US-20250136600-A1 | POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM1, CHRM3 | KDM4E 753/4885ALDH1A1 2993/4885HPGD 1730/4885 |
| US-12398117-B2 | Heteroarylamidopyridinol derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of autoimmune disease | IL6, TRAF6, CD14 | KDM4E 978/4885ALDH1A1 1799/4885HPGD 586/4885 |
| US-20250228811-A1 | Triester Compounds And Methods Of Use Thereof | CYP46A1, CYP17A1, CYP27A1 | KDM4E 2546/4885ALDH1A1 1167/4885HPGD 815/4885 |
| US-12344608-B2 | Positive modulators of the muscarinic acetylcholine receptor M4 | CHRM4, CHRM1, CHRM3 | KDM4E 753/4885ALDH1A1 2993/4885HPGD 1730/4885 |
| US-20090156648-A1 | Preparations containing pyridoxine and alpha-hydroxyisocaproic acid (HICA) | PNPO, CYP3A5, CYP8B1 | KDM4E 1424/4885ALDH1A1 871/4885HPGD 17/4885 |
| US-20250122199-A1 | POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM1, CHRM3 | KDM4E 753/4885ALDH1A1 2993/4885HPGD 1730/4885 |
| US-20260035366-A1 | POSITIVE MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM3, CHRM5 | KDM4E 775/4885ALDH1A1 3334/4885HPGD 1698/4885 |
| US-12448380-B2 | Positive modulators of the muscarinic acetylcholine receptor M4 | CHRM4, CHRM1, CHRM3 | KDM4E 753/4885ALDH1A1 2993/4885HPGD 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.